Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will par...
The analysts at Citi have downgraded Unity Biotechnology ([[UBX]] +3.0%) to sell from neutral noting a near three-fold rise in company share price since August without a ‘meaningful enough change in fundamentals.’However, the firm raises the price target to $6 from $5, a ~26.9% ...
Scientists at Unity Biotechnology (UBX) and the University of Montreal say that they have discovered a novel mechanism of action for treating diseases such as diabetic retinopathy and diabetic macular edema.The approach focuses on restoring vascular health in the retina.The research, publishe...
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY Biotechnology and University of Montreal provide mechanistic evidence supporting potential ...
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations SOUTH SAN FRANCISCO, Calif., Feb. 01, ...
Gainers: [[CLSD]] +9.9%. [[EBON]] +3.8%. [[ETM]] +3.6%. [[CVE]] +3.6%. [[UBX]] +3.6%.Losers: [[CGA]] -12.2%. [[CNF]] -12.1%. [[WBAI]] -10.7%. [[SCYX]] -9.2%. [[NRO]] -8.8%. For further details see: CLSD, EBON, CGA and CNF among after-hours movers
Jacobio raised $174 million in a Hong Kong IPO to develop its portfolio of 12 novel drugs. WuXi Biologics will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany. CASI Pharma announced its partnered CD19 CAR-T product was granted Breakthrough De...
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from December 1, 2020 through December 15, 2020, t...
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and Brain SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- UNITY B...
Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on August 17 due to it failing to meet its primary endpoint in Unity’s ongoing Phas...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been e...